J&J first-quarter results
This article was originally published in The Rose Sheet
Executive Summary
The strong performance of skin-care lines Aveeno and Clean & Clear helped drive worldwide consumer sales up 48.5% to $3.5 bil. for the first quarter 2007, company announces April 17. J&J's combined consumer business - which includes skin care, baby and kids care, oral care, OTCs and nutritionals and women's health - increased 41.7% domestically to $1.6 bil. and 54.9% internationally to $1.9 bil. for the quarter, firm says. In the U.S., skin-care sales rose 13% to $357 mil., baby and kids care increased 5% to $109 mil., and oral care booked $203 mil. in revenue. J&J acquired Pfizer Consumer Healthcare in December 2006 (1"The Rose Sheet" Jan. 1, 2007, In Brief)...
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.